Novelion Therapeutics Inc. Common Shares
NVLN
NVLN was delisted on the 8th of October, 2019.
35 hedge funds and large institutions have $8.68M invested in Novelion Therapeutics Inc. Common Shares in 2019 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 6 increasing their positions, 5 reducing their positions, and 6 closing their positions.
27% more capital invested
Capital invested by funds: $6.86M → $8.68M (+$1.82M)
20% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 5
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
3% less funds holding
Funds holding: 36 → 35 (-1)
17% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$69.1K |
| 2 |
EIG
EdgePoint Investment Group
Toronto,
Ontario, Canada
|
+$59.7K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$6.42K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$2.25K |
| 5 |
JP Morgan Chase
New York
|
+$1.55K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Broadfin Capital
New York
|
-$569K |
| 2 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$447K |
| 3 |
Millennium Management
New York
|
-$42.3K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$42K |
| 5 |
VF
Virtu Financial
New York
|
-$25K |
NVLN Hedge Fund Activity: Q1 2019 in Review
35 of the 4,633 institutional investors tracked by Wall St. Rank reported a position in Novelion Therapeutics Inc. Common Shares (NVLN) for Q1 2019, worth a combined $8.68M — up 27% from $6.86M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of NVLN and 5 opened new positions — a net loss of 1 holder — while 5 trimmed existing stakes and 6 added.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $69.1K. The largest seller was Broadfin Capital, cutting an estimated $569K.
- 35 institutional investors held Novelion Therapeutics Inc. Common Shares (NVLN) as of Q1 2019, down from 36 in Q4 2018.
- Funds reported $8.68M of Novelion Therapeutics Inc. Common Shares stock for Q1 2019, up 27% quarter-over-quarter.
- 5 funds opened new Novelion Therapeutics Inc. Common Shares positions in Q1 2019 and 6 closed out, a net change of -1 holder.
- The largest Novelion Therapeutics Inc. Common Shares buyer in Q1 2019 was Citadel Advisors, an estimated $69.1K added.
- The largest Novelion Therapeutics Inc. Common Shares seller in Q1 2019 was Broadfin Capital, an estimated $569K sold.
Based on aggregated 13F filings for Q1 2019.